Proscia is a technology company.
Proscia has raised $90.0M across 4 funding rounds.
Key people at Proscia.
Proscia has raised $90.0M in total across 4 funding rounds.
Proscia has raised $90.0M in total across 4 funding rounds.
Proscia's investors include Alumni Ventures, Day One Ventures, Aniq Kassam, Fusion Fund, Hummingbird Ventures, Indicator Ventures, Insight Partners, Pareto Holdings, TSVC Capital, Valhalla Ventures, What If Ventures, Bradley Horowitz.
Key people at Proscia.
Proscia is a software company transforming pathology from analog microscope-based practices to a digital, AI-driven discipline, primarily through its Concentriq enterprise pathology platform.[1][3][6] It serves pharmaceutical companies, research organizations, academic medical centers, health systems, and diagnostic labs by enabling high-resolution image management, analysis, sharing, and AI integration to accelerate cancer research, diagnostics, and precision medicine.[1][2][6] The platform addresses core challenges like siloed data, inefficient workflows, and limited collaboration, with products like Concentriq LS for life sciences, Concentriq AP for labs, and FDA-cleared Concentriq AP-Dx for primary diagnosis—on track to support over 22,000 daily patient diagnoses in 2025 while powering novel therapies for 16 of the top 20 pharma companies.[1][3][4][6] Proscia demonstrates strong growth momentum, with revenue more than doubling in 2024 amid surging adoption, $130M in funding, and recognitions like the 2025 MedTech Breakthrough Award.[1][3][4]
Proscia was founded to modernize pathology with software, recognizing pathologists and scientists as key to advancing medicine amid outdated analog tools.[3][9] While specific founders are not detailed in available sources, the company emerged to tackle microscope-based limitations in biomedical research and diagnostics, such as inaccessible tissue images and collaboration barriers.[2][9] Early traction built through Concentriq's development as a scanner-agnostic platform integrating with major imaging hardware, lab systems, and AI, earning certifications like ISO 27001 and FDA 510(k) clearance for AP-Dx.[3][5] Pivotal moments include partnerships with global labs like the Jackson Laboratory Cancer Center (JPC) for digitizing vast tissue repositories, explosive 2024 growth with 12+ platform updates and a precision medicine AI portfolio of 120+ apps, and expansion of customer experience teams to support mission-critical deployments.[2][4]
Proscia rides the digital pathology and AI wave in precision medicine, digitizing tissue analysis to unlock data for faster drug development, trials, and diagnostics amid rising cancer burdens.[1][5][9] Timing is ideal as pathology mainstreams—AI adoption accelerates, interoperable infrastructure demand surges, and labs shift to 100% digital for efficiency and collaboration.[4][5][6] Market forces like pharma's need for real-world evidence, regulatory clearances easing clinical use, and global lab networks (e.g., 14-16 top pharmas) favor Proscia, positioning it as connective tissue reducing bottlenecks and enabling scalable growth.[1][4][5] It influences the ecosystem by fostering AI research ecosystems, partnering with CROs/hospitals, and bridging discovery-to-diagnosis, ultimately speeding therapies and improving outcomes.[2][6][9]
Proscia is primed for continued dominance as digital pathology becomes standard care, with next steps including broader AI clinical deployments, Aperture expansions for real-world evidence, and global lab network growth beyond 8M+ diagnoses.[1][4][7][9] Trends like multi-modal AI integration, regulatory tailwinds, and precision medicine demand will propel it, potentially solidifying Concentriq as the industry backbone.[5][8] Its influence may evolve from enabler to ecosystem orchestrator, rewiring pathology for unprecedented breakthroughs—reinforcing its role in turning analog data into actionable insights that save lives.[1][6]
Proscia has raised $90.0M across 4 funding rounds. Most recently, it raised $50.0M Series D in March 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2025 | $50.0M Series D | Alumni Ventures, Day One Ventures, Aniq Kassam, Fusion Fund, Hummingbird Ventures, Indicator Ventures, Insight Partners, Pareto Holdings, TSVC Capital, Valhalla Ventures, What If Ventures, Bradley Horowitz, Matt Mickiewicz | |
| Jan 1, 2024 | $9.0M Series C | Addition, Day One Ventures, Fusion Fund, Hummingbird Ventures, Indicator Ventures, Scale Venture Partners, Shine Capital, SNR, Valhalla Ventures, Matt Mickiewicz | |
| Nov 1, 2020 | $23.0M Series B | Addition, Scale Venture Partners, Shine Capital, SNR | |
| Sep 1, 2018 | $8.0M Series A | Comal Ventures, Day One Ventures, FJ Labs, Flybridge, Fusion Fund, Hummingbird Ventures, Indicator Ventures, Matchstick Ventures, Ulu Ventures, Valhalla Ventures, Yamaha Motor Ventures, Matt Mickiewicz, Shane Neman |
